BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd.
About BioCryst Pharmaceuticals, Inc.
BioCryst uses state-of-the-art structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates. In December 2014, RAPIVABÂ® was approved by the FDA, the first U.S. approval for a BioCryst discovered drug.
BioCryst's current pipeline consists of the following development programs:
- Oral inhibitors of plasma kallikrein for hereditary angioedema; BCX7353 and other 2nd generation candidates
- BCX4430 a broad spectrum antiviral for development as a medical countermeasure against hemorrhagic fevers
Drug Development is a Journey. Watch BioCryst pushing forward for Hereditary Angioedema (HAE) patients.
355 articles with BioCryst Pharmaceuticals, Inc.
Here’s a roundup of some of the top clinical trial news from the previous week.
Despite hitting endpoints in the late-stage trial, BioCryst's BCX7353 results do not stack up against Takeda's Takhzyro, which was approved last year.
BioCryst Pharmaceuticals, Inc. today announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period.
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2018. “Building on the clear direction from our shareholders and a strong conviction in the medical community that BCX7353 is a highly differentiated asset which can deliver enormous value to patients and shareholders, we have made substantial progress advancing our prophylactic and acute BCX7353 clinical progra
BioCryst Pharmaceuticals, Inc. announced that the Company has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE).
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. announced the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
BioCryst Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock, offered at a price to the public of $5.50 per share.
BioCryst Pharmaceuticals, Inc. announced that it is offering to sell $50 million of its common stock in an underwritten public offering.
Provided an update on the Company’s strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals and BioCryst Pharmaceuticals originally planned on January 22, 2018 to merge the two companies. Now the two companies announced the deal has been terminated.
BioCryst Pharmaceuticals, Inc. announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held today.
BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan
BCX7353 continues development under Sakigake designation
BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera
Powerful IMO-2125 Data from ILLUMINATE-204 Trial Further Supports Value of Combination
BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals
BioCryst Mails Letter to Stockholders Highlighting Compelling Upside Opportunity
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) announced a string of approvals, as well as a couple rejections.
The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board.
BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossifica...
1/5/2018FOP is a very rare disease that affects approximately 1 in 2 million people worldwide.
For the three months ended September 30, 2017, revenues increased to $8.8 million from $7.8 million in the third quarter of 2016.
BioCryst will host a conference call and webcast at 11:00 a.m. ET to discuss financial results and to provide an update regarding the Company's clinical development programs.